Oral vs Intravenous Antibiotics for Fracture-Related Infections: The POvIV Randomized Clinical Trial.

IF 15.7 1区 医学 Q1 SURGERY
William T Obremskey, Robert V O'Toole, Saam Morshed, Paul Tornetta, Clinton K Murray, Clifford B Jones, Daniel O Scharfstein, Tara J Taylor, Anthony R Carlini, Jennifer M DeSanto, Renan C Castillo, Michael J Bosse, Madhav A Karunakar, Rachel B Seymour, Stephen H Sims, David A Weinrib, Christine Churchill, Eben A Carroll, Holly T Pilson, James Brett Goodman, Martha B Holden, Anna N Miller, Debra L Sietsema, Philip F Stahel, Hassan Mir, Andrew H Schmidt, Jerald R Westberg, Brian Mullis, Karl D Shively, Robert A Hymes, Sanjit R Konda, Heather A Vallier, Mary Alice Breslin, Christopher S Smith, Colin V Crickard, J Spence Reid, Mitch Baker, W Andrew Eglseder, Christopher LeBrun, Theodore Manson, Daniel C Mascarenhas, Jason Nascone, Andrew N Pollak, Michael G Schloss, Marcus F Sciadini, Yasmin Degani, Theodore Miclau, David B Weiss, Seth R Yarboro, Eric D McVey, Reza Firoozabadi, Julie Agel, Eduardo J Burgos, Vamshi Gajari, Andres Rodriguez-Buitrago, Rajesh R Tummuru, Karen M Trochez
{"title":"Oral vs Intravenous Antibiotics for Fracture-Related Infections: The POvIV Randomized Clinical Trial.","authors":"William T Obremskey, Robert V O'Toole, Saam Morshed, Paul Tornetta, Clinton K Murray, Clifford B Jones, Daniel O Scharfstein, Tara J Taylor, Anthony R Carlini, Jennifer M DeSanto, Renan C Castillo, Michael J Bosse, Madhav A Karunakar, Rachel B Seymour, Stephen H Sims, David A Weinrib, Christine Churchill, Eben A Carroll, Holly T Pilson, James Brett Goodman, Martha B Holden, Anna N Miller, Debra L Sietsema, Philip F Stahel, Hassan Mir, Andrew H Schmidt, Jerald R Westberg, Brian Mullis, Karl D Shively, Robert A Hymes, Sanjit R Konda, Heather A Vallier, Mary Alice Breslin, Christopher S Smith, Colin V Crickard, J Spence Reid, Mitch Baker, W Andrew Eglseder, Christopher LeBrun, Theodore Manson, Daniel C Mascarenhas, Jason Nascone, Andrew N Pollak, Michael G Schloss, Marcus F Sciadini, Yasmin Degani, Theodore Miclau, David B Weiss, Seth R Yarboro, Eric D McVey, Reza Firoozabadi, Julie Agel, Eduardo J Burgos, Vamshi Gajari, Andres Rodriguez-Buitrago, Rajesh R Tummuru, Karen M Trochez","doi":"10.1001/jamasurg.2024.6439","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Fracture-related infection (FRI) is a serious complication following fracture fixation surgery. Current treatment of FRIs entails debridement and 6 weeks of intravenous (IV) antibiotics. Lab data and retrospective clinical studies support use of oral antibiotics, which are less expensive and may have fewer complications than IV antibiotics.</p><p><strong>Objective: </strong>To evaluate the effectiveness of treatment of FRI with oral vs IV antibiotics.</p><p><strong>Design, setting, and participants: </strong>The POvIV multicenter, prospective randomized clinical trial was conducted across 24 trauma centers in the US among patients aged 18 to 84 years who had fracture repair or arthrodesis with fixation with implants and developed an FRI without radiographic evidence of osteomyelitis. Patients were enrolled between March 2013 and September 2018 and followed up for 12 months after hospitalization for treatment of their FRI.</p><p><strong>Intervention: </strong>Oral vs IV antibiotics following FRI.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was number of surgical interventions, and the primary hypothesis was noninferiority of oral vs IV antibiotics with respect to the number of study injury-related surgical interventions by 1 year. Unadjusted modified intent-to-treat (mITT) and adjusted per-protocol (PP) analyses were prespecified. A post hoc adjusted mITT analysis was conducted to resolve discrepancies between the results of the prespecified mITT and PP analyses. Recurrence of a deep surgical site infection was a key secondary outcome.</p><p><strong>Results: </strong>Among 233 total patients, mean (SD) age was 46.0 (13.9) years, and 53 patients were female (22.7%). The mean number of surgical interventions within 1 year was 1.3 and 1.1 for the oral and IV groups, respectively. The upper bound of the 95% confidence interval of the mean difference with unadjusted mITT analysis was 0.59, which was lower than the prespecified noninferiority margin of 0.67, indicating noninferiority of oral to IV antibiotics. Adjusted PP analysis did not support noninferiority of the number of reoperations. A post hoc adjusted mITT analysis also showed noninferiority. The treatment effects estimates for the key secondary outcome of reinfection showed a similar pattern as those for the primary outcome.</p><p><strong>Conclusions and relevance: </strong>In this prospective randomized clinical trial, oral antibiotic treatment was noninferior to IV treatment with respect to the primary outcome of number of surgical interventions based on mITT analysis. However, there is some uncertainty in these findings based on preplanned and post hoc secondary analyses. A similar pattern of treatment effect estimates was observed for the secondary outcome of recurrence of infection.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT01714596.</p>","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamasurg.2024.6439","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: Fracture-related infection (FRI) is a serious complication following fracture fixation surgery. Current treatment of FRIs entails debridement and 6 weeks of intravenous (IV) antibiotics. Lab data and retrospective clinical studies support use of oral antibiotics, which are less expensive and may have fewer complications than IV antibiotics.

Objective: To evaluate the effectiveness of treatment of FRI with oral vs IV antibiotics.

Design, setting, and participants: The POvIV multicenter, prospective randomized clinical trial was conducted across 24 trauma centers in the US among patients aged 18 to 84 years who had fracture repair or arthrodesis with fixation with implants and developed an FRI without radiographic evidence of osteomyelitis. Patients were enrolled between March 2013 and September 2018 and followed up for 12 months after hospitalization for treatment of their FRI.

Intervention: Oral vs IV antibiotics following FRI.

Main outcomes and measures: The primary outcome was number of surgical interventions, and the primary hypothesis was noninferiority of oral vs IV antibiotics with respect to the number of study injury-related surgical interventions by 1 year. Unadjusted modified intent-to-treat (mITT) and adjusted per-protocol (PP) analyses were prespecified. A post hoc adjusted mITT analysis was conducted to resolve discrepancies between the results of the prespecified mITT and PP analyses. Recurrence of a deep surgical site infection was a key secondary outcome.

Results: Among 233 total patients, mean (SD) age was 46.0 (13.9) years, and 53 patients were female (22.7%). The mean number of surgical interventions within 1 year was 1.3 and 1.1 for the oral and IV groups, respectively. The upper bound of the 95% confidence interval of the mean difference with unadjusted mITT analysis was 0.59, which was lower than the prespecified noninferiority margin of 0.67, indicating noninferiority of oral to IV antibiotics. Adjusted PP analysis did not support noninferiority of the number of reoperations. A post hoc adjusted mITT analysis also showed noninferiority. The treatment effects estimates for the key secondary outcome of reinfection showed a similar pattern as those for the primary outcome.

Conclusions and relevance: In this prospective randomized clinical trial, oral antibiotic treatment was noninferior to IV treatment with respect to the primary outcome of number of surgical interventions based on mITT analysis. However, there is some uncertainty in these findings based on preplanned and post hoc secondary analyses. A similar pattern of treatment effect estimates was observed for the secondary outcome of recurrence of infection.

Trial registration: ClinicalTrials.gov Identifier: NCT01714596.

口服与静脉注射抗生素治疗骨折相关感染:POvIV随机临床试验
重要性:骨折相关感染(FRI)是骨折固定手术后的严重并发症。目前fri的治疗需要清创和6周静脉注射抗生素。实验室数据和回顾性临床研究支持使用口服抗生素,因为口服抗生素比静脉注射抗生素更便宜,并发症也更少。目的:评价口服与静脉注射抗生素治疗FRI的疗效。设计、环境和参与者:POvIV多中心、前瞻性随机临床试验在美国24个创伤中心进行,患者年龄在18至84岁之间,接受骨折修复或关节融合术,植入物固定,发生FRI,没有骨髓炎的影像学证据。患者于2013年3月至2018年9月期间入组,并在住院后随访12个月,以治疗其fri。干预措施:fri后口服与静脉注射抗生素。主要结局和措施:主要结局是手术干预次数,主要假设是口服与静脉注射抗生素对研究损伤相关手术干预次数的非劣效性。未调整的修改意向治疗(mITT)和调整后的协议分析(PP)是预先指定的。进行了事后调整的mITT分析,以解决预先指定的mITT和PP分析结果之间的差异。深部手术部位感染的复发是一个关键的次要结果。结果:233例患者中,平均(SD)年龄46.0(13.9)岁,女性53例(22.7%)。口服组和静脉注射组1年内平均手术次数分别为1.3次和1.1次。未经调整的mITT分析平均差异的95%置信区间上限为0.59,低于预先设定的非劣效性边际0.67,表明口服抗生素与静脉注射抗生素具有非劣效性。调整后的PP分析不支持再手术次数的非劣效性。事后调整的mITT分析也显示出非劣效性。再感染这一关键次要结局的治疗效果估计与主要结局的治疗效果估计相似。结论和相关性:在这项前瞻性随机临床试验中,根据mITT分析,就手术干预次数的主要结局而言,口服抗生素治疗不逊于静脉注射治疗。然而,基于预先计划和事后的二次分析,这些发现存在一些不确定性。对于感染复发的次要结局,观察到类似的治疗效果估计模式。试验注册:ClinicalTrials.gov标识符:NCT01714596。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA surgery
JAMA surgery SURGERY-
CiteScore
20.80
自引率
3.60%
发文量
400
期刊介绍: JAMA Surgery, an international peer-reviewed journal established in 1920, is the official publication of the Association of VA Surgeons, the Pacific Coast Surgical Association, and the Surgical Outcomes Club.It is a proud member of the JAMA Network, a consortium of peer-reviewed general medical and specialty publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信